Empagliflozin (BI 107730) is a Selective SGLT-2 Inhibitor for Type 2 Diabetes Research
Diabetes has a major impact on the global human population. Generally, blood glucose control is the major method of diabetes treatment. Previous studies indicated that targeting sodium glucose co-transporter-2 (SGLT-2)…